Bristol J A, Schlom J, Abrams S I
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA.
Cell Immunol. 1999 May 25;194(1):78-89. doi: 10.1006/cimm.1999.1489.
Adoptive T-cell transfer has been shown to be a potentially effective strategy for cellular immunotherapy in some murine models of disease. However, several issues remain unresolved regarding some of the basic features involved in effective adoptive transfer, such as the influence of specific peptide antigen (Ag) boost after T-cell transfer, the addition of IL-2 post-T-cell transfer, the trafficking of transferred T cells to lymphoid and nonlymphoid tissues, and the functional stability of recoverable CD4(+) and CD8(+) T cells. We investigated several of these parameters, particularly as they relate to the persistence and maintenance of effector functions of murine CD4(+) and/or CD8(+) T lymphocytes after adoptive cellular transfer into partially gamma-irradiated syngeneic hosts. Our laboratory previously identified murine (H-2(d)) immunogenic CD4(+) and CD8(+) T-cell peptide epitopes reflecting codon 12 ras mutations as tumor-specific Ag. Therefore, the model system chosen here employed epitope-specific MHC class II-restricted CD4(+) T cells and MHC class I-restricted CD8(+) T cells produced from previously immunized BALB/c mice. Between 2 and 7 days after T-cell transfer, recipient mice received various combinations of peptide boosts and/or IL-2 treatments. At different times after the T-cell transfer, spleen and lung tissues were analyzed phenotypically to monitor the persistence of the immune T cells and functionally (via proliferation or cytotoxicity assays) to assess the maintenance of peptide specificity. The results showed that immune donor T lymphocytes (uncultured immune T cells or cloned T cells) were recoverable from the spleens and lungs of recipient mice after transfer. The recovery of Ag-specific T-cell responses was greatest from recipient mice that received peptide boosts and IL-2 treatment. However, mice that received a peptide boost without IL-2 treatment responded nearly as well, which suggested that including a peptide boost after T-cell transfer was more obligatory than exogenous IL-2 treatment to sustain adoptively transferred T cells in vivo. Ag-specific T-cell responses were weak in mice that either received IL-2 alone or did not receive the cognate peptide boost after T-cell transfer. The T-cell clones were also monitored by flow cytometry or RT-PCR based on expression of the T-cell receptor Vbeta-chain, which was previously characterized. Ag-specific T cells were recovered from both spleens and lungs of recipient mice, demonstrating that the T-cell clones could localize to both lymphoid and nonlymphoid tissues. This study demonstrates that both uncultured and in vitro-cloned T lymphocytes can migrate to lymphoid tissues and nonlymphoid (e.g., lung) tissues in recipient hosts and that their functional activities can be maintained at these sites after transfer, if they are exposed to peptide Ag in vivo.
在一些疾病的小鼠模型中,过继性T细胞转移已被证明是一种潜在有效的细胞免疫治疗策略。然而,关于有效过继性转移所涉及的一些基本特征,仍有几个问题尚未解决,例如T细胞转移后特异性肽抗原(Ag)增强的影响、T细胞转移后IL-2的添加、转移的T细胞向淋巴组织和非淋巴组织的迁移,以及可恢复的CD4(+)和CD8(+) T细胞的功能稳定性。我们研究了其中的几个参数,特别是它们与过继性细胞转移到部分γ射线照射的同基因宿主后小鼠CD4(+)和/或CD8(+) T淋巴细胞效应功能的持久性和维持有关。我们实验室之前鉴定出反映密码子12 ras突变的小鼠(H-2(d))免疫原性CD4(+)和CD8(+) T细胞肽表位作为肿瘤特异性Ag。因此,这里选择的模型系统采用了由先前免疫的BALB/c小鼠产生的表位特异性MHC II类限制性CD4(+) T细胞和MHC I类限制性CD8(+) T细胞。在T细胞转移后2至7天,受体小鼠接受肽增强和/或IL-2治疗的各种组合。在T细胞转移后的不同时间,对脾脏和肺组织进行表型分析以监测免疫T细胞的持久性,并进行功能分析(通过增殖或细胞毒性测定)以评估肽特异性的维持。结果表明,转移后可从受体小鼠的脾脏和肺中回收免疫供体T淋巴细胞(未培养的免疫T细胞或克隆的T细胞)。接受肽增强和IL-2治疗的受体小鼠中Ag特异性T细胞反应的恢复最大。然而,接受肽增强但未接受IL-2治疗的小鼠反应也几乎一样好,这表明T细胞转移后包括肽增强比外源性IL-2治疗对于在体内维持过继性转移的T细胞更必不可少。在T细胞转移后单独接受IL-2或未接受同源肽增强的小鼠中,Ag特异性T细胞反应较弱。还基于先前表征的T细胞受体Vβ链的表达通过流式细胞术或RT-PCR监测T细胞克隆。从受体小鼠的脾脏和肺中都回收了Ag特异性T细胞,表明T细胞克隆可以定位于淋巴组织和非淋巴组织。这项研究表明,未培养的和体外克隆的T淋巴细胞都可以迁移到受体宿主的淋巴组织和非淋巴(例如肺)组织,并且如果它们在体内暴露于肽Ag,转移后它们的功能活性可以在这些部位维持。